SUNNYVALE, Calif. -- Radiation therapy system maker Accuray said Friday that healthcare executive Joshua Levine will be its new CEO, replacing Euan Thomson, its head for the past decade.
Thomson had been Accuray's president and CEO since 2002. He also resigned from its board of directors. He said that it was "time for change" and that a "change in leadership is healthy for the organization." Accuray said that Thomson will likely consult for the company. Under him, Accuray Inc. went public, in 2007, and last year bought a former rival, TomoTherapy.
Levine, 54, has taken Thomson's place as president and CEO and his position on the board. He has most recently been CEO of blood-testing equipment maker Immucor Corp., which was acquired by private equity firm TPG Capital in October 2011. Before that, he was CEO of breast implant maker Mentor Corp., which was sold to a unit of Johnson & Johnson in 2009.
During a conference call with analysts, Levine said that Accuray was not exploring strategic options and was trying to expand the business with two product launches later this month.
Shares of the Sunnyvale, Calif., company dipped 2 cents to $7. Shares have risen by two-thirds this year.